Key Takeaways
- The TME includes immune cells, fibroblasts, endothelial cells, extracellular matrix, and signaling molecules.
- Bulk, imaging-based, sequencing-based, and spatially resolved methods each capture different aspects of the TME.
- Single biomarkers can have limited predictive value. PD-L1, for example, was predictive in 28.9% of FDA immune checkpoint inhibitor approval cases analyzed in a 2019 study, not 28.9% of patients.
- Laser capture microdissection (LCM) can isolate tumor, stromal, or immune-rich regions for compartment-specific molecular analysis.
- Sample preservation, defined objectives, and orthogonal validation reduce common sources of error.
What Is the Tumor Microenvironment?
The TME comprises malignant cells and the surrounding cellular and non-cellular environment. Alongside tumor cells, its major components include:
- Immune cells: T cells, B cells, natural killer cells, macrophages, and dendritic cells.
- Stromal cells: cancer-associated fibroblasts (CAFs) and endothelial cells.
- Extracellular matrix: structural proteins that organize the tissue.
- Signaling molecules: cytokines, chemokines, and growth factors exchanged between cells.
These components participate in processes such as angiogenesis, invasion, and immune evasion (Tumor Microenvironment, 2020). Immune infiltration is often described in patterns such as inflamed, excluded, or immune-desert, which depend on where immune cells are located relative to tumor cells.
Why TME Analysis Matters in Cancer Research
Tumor cells, immune cells, and fibroblasts interact through direct contact and secreted signals. CAFs, for example, include several subtypes with different reported functions in tumor progression (Experimental & Molecular Medicine, 2023).
TME analysis supports research on:
- Biomarker identification and validation in tissue context
- Mechanisms of response and resistance to immunotherapy
- Spatial relationships that bulk measurements average out
- Combination strategies that target more than one TME component
The Limits of a Single Biomarker
A 2019 analysis evaluated PD-L1 as a predictive biomarker across 45 FDA approvals of immune checkpoint inhibitors from 2011 to April 2019 (Davis and Patel, 2019). PD-L1 was predictive in 28.9% of those approval cases, not predictive in 53.3%, and not tested in 17.8%. These percentages describe approval cases, not patient-level response rates. Approved thresholds included 1%, 5%, and 50%, and expression was measured on tumor cells, immune cells, or both.
These findings illustrate why researchers often combine several measurements of the TME rather than relying on one marker.
Methods Used in TME Analysis
| Method | What it measures | Spatial information | Main limitation |
|---|---|---|---|
| Bulk RNA or protein profiling | Average expression across the sample | None | Mixes signals from all cell types |
| Immunohistochemistry (IHC) | One or a few proteins per section | Retained | Limited multiplexing |
| Multiplex immunofluorescence | Several proteins in one section | Retained | Panel design and spectral overlap |
| Spatial transcriptomics | Gene expression by location | Retained | Cost, resolution, and data analysis demands |
| LCM with molecular analysis | DNA, RNA, or protein from selected regions | Documented at selection | Lower throughput |
LCM is a tissue-isolation method. It differs from spatial transcriptomics, which measures expression in place, and from imaging methods, which visualize markers without removing tissue.
A Typical TME Analysis Workflow
1. Define the Research Objective
Decide whether the aim is to quantify a biomarker, profile immune cells, map spatial organization, or isolate populations for molecular analysis. This choice determines sample handling and methods.
2. Collect and Preserve Tissue
- Fresh-frozen tissue generally preserves RNA and labile protein modifications better.
- FFPE tissue is widely available in archives and suits IHC. In a 2023 study of paired fresh, frozen, and FFPE cardiac tissue, RNA from FFPE tissue was more degraded and sequencing yielded more intronic and intergenic reads (PLOS ONE, 2023). Those findings are study-specific to the tissues and methods reported.
3. Isolate Target Regions
LCM can collect tumor epithelium, stroma, or immune-rich regions separately. The workflow usually involves staining, visual selection of the target region, laser capture or cutting, and collection for downstream analysis.
4. Apply Imaging or Molecular Analysis
Depending on the objective, this may include IHC or multiplex immunofluorescence, spatial transcriptomics, or qPCR and sequencing of microdissected material.
5. Interpret and Validate
Image analysis can quantify cell densities, distances, and marker co-expression. Spatial transcriptomics findings are commonly validated with IHC or other orthogonal methods.
Example: Comparing Immune Cells at the Tumor Border
A researcher comparing immune activation inside and outside a tumor-stroma boundary might:
- Select sections with a clear tumor-stroma boundary.
- Microdissect tumor-border and stromal regions separately.
- Profile each region by RNA or protein analysis.
- Compare activation markers by location, with replicate samples and controls.
Clean region boundaries, replicate sampling, and validation controls help avoid misleading comparisons.
Laxco Tools for TME Research
Researchers who need compartment-specific molecular data may consider LCM. Laxco's Accuva Cellect Laser Capture Microdissection System is designed for this:
- Dual-laser design: an infrared (IR) laser for capture of single cells or small numbers of cells, and a UV laser for cutting dense structures.
- Sample preparation: Laxco lists FFPE and fresh-frozen tissue, H&E-stained and LCM-optimized stains, immunofluorescence, unstained samples, and cell culture.
- Software workflow: a five-step workflow supports target selection, visual quality control, and documentation.
- Footprint: approximately 32% smaller than comparable microscope-and-laser systems, according to Laxco. Confirm the exact dimensions for the selected configuration before planning bench space.
For image quantification, Laxco's LEAP AI is a separate microscopy and image-analysis platform that combines Accuva LEAP optics with Media Cybernetics Image-Pro AI. It is not built into Accuva Cellect, does not automatically select cells for Cellect capture, and does not control the Cellect laser. It provides pre-trained deep-learning segmentation, measurement, batch processing, and reporting. Automated segmentation can reduce some sources of analyst-to-analyst variability when validated for the tissue and staining used.
For multichannel immunofluorescence imaging, the SLi6Pro inverted widefield fluorescence microscope uses SeBaLIT™ LED-based illumination and supports 3-color multiplex fluorescence across approximately 390-662 nm with more than 110 compatible fluorochromes. The 110+ figure is fluorochrome compatibility, not simultaneous imaging of 110 channels.
Laxco lists training and 48-hour response times for Accuva Cellect. Confirm available training formats and service terms with Laxco. Laxco does not perform tumor analysis or pathology services.
Frequently Asked Questions
Should I use spatial transcriptomics or LCM for TME studies?
Spatial transcriptomics measures gene expression at defined positions within tissue, with coverage and resolution depending on the platform. LCM physically isolates selected cells or compartments, such as tumor nests, invasive margins, or stroma, for separate molecular analysis. Sequencing or proteomics of the captured material produces a profile associated with the selected region, rather than a continuous spatial map. The depth and coverage of that profile depend on sample input and the downstream assay. The two approaches complement each other when spatial measurements identify regions that require targeted molecular follow-up.
Why is a single biomarker often not enough in TME studies?
Single biomarkers can have limited predictive value. A 2019 analysis of 45 FDA immune checkpoint inhibitor approvals reported that PD-L1 was predictive in 28.9% of those approval cases (Davis and Patel, 2019), not 28.9% of patients. Spatial context can add information that one marker lacks.
Can AI image analysis quantify immune infiltration?
Yes. Segmentation can count immune cells and measure their distance from tumor regions. LEAP AI is a separate imaging and analysis platform that provides pre-trained deep-learning segmentation; it is not an Accuva Cellect feature. Results should be validated against pathologist annotation for each tissue and stain.
Which sample types can Accuva Cellect isolate cells from?
Laxco lists FFPE and fresh-frozen tissue, H&E-stained and LCM-optimized stained sections, immunofluorescence, unstained samples, and cell culture. Fresh-frozen tissue usually gives better RNA quality for TME expression studies.
What should I compare before requesting a quote?
Define your tissue types, compartments of interest, downstream assays, and sample volume. Accuva Cellect and LEAP AI are separate platforms with different roles. A Laxco specialist can advise on fit and confirm compatibility for your tumor microenvironment workflow.
